I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 301 210 247 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

10/10/03 (Gin/y Blundell) Docket No.: CIBT-P03-130

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Huston et al.

Application No.: Not Yet Assigned

Confirmation No.:

Filed: October 10, 2003

Art Unit: N/A

For:

BIOSYNTHETIC BINDING PROTEINS FOR

IMMUNO-TARGETING

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Those patent(s) or publications(s) in the attached from Form PTO-1449 are not supplied because they were previously cited by or submitted to the Office in a prior application number 09/325602, filed June 3, 1999 and relied upon in this application for an earlier filing date under 35 U.S.C. 120.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this

Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. CIBT-P03-130. A duplicate copy of this paper is enclosed.

Dated: October 10, 2003

Respectfully submitted,

Melissa S. Rones, Ph.D.

Registration No.: 54,408

ROPES & GRAY LLP One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant

9276638_1

Application/Control No. Applicant(s)/Patent Under Reexamination 09/558,741 HUSTON ET AL. Notice of References Cited Examiner Art Unit Page 1 of 1 Larry R. Helms 1642 **U.S. PATENT DOCUMENTS Document Number** Date Name Country Code-Number-Kind Code Classification MM-YYYY Α US-6,207,804 03-2001 Huston et al В US-US-С US-D Ε US-F US-G USн US-1 US-US-J Κ US-L US-М US-FOREIGN PATENT DOCUMENTS Document Number Date Country Code-Number-Kind Code Country MM-YYYY Name Classification Ν O Р Q R s Т **NON-PATENT DOCUMENTS** Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages) U Klausner, BioTechnology 4:1041 and 1043, 12/86 Rudikoff et al., Proc. Natl. Acad. Sci. USA 79:1979-83, 1982 W Pastan et al., Cell 47:641-648, 12/86

"A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Jones et al., Nature 321:522-25, 5/86

Х

COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

O I A K SC138

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if pages and)

(Use several sheets if necessary)
Sheet 1 of 1

In the AMARKS of James S. HUSTON, et al.

Serial No.: 09/558,741

Filed: April 26, 2000

•

Art Unit: 1644

Examiner: T. Cunningham

Title: BIOSYNTHETIC BINDING PROTEINS FOR IMMUNO-TARGETING

ASTATCA

10

出山

U.S. PATENT DOCUMENTS

Exam. Init.	Ref. Desig.	Document No.	Date	Name	Class	Sub Class	Filing Date
101	AA-1	5,877;305	March 2	, 1999 Huston et al.			
M	AB-1	6,054,561	April 25	, 2000 Ring			

FOREIGN PATENT DOCUMENTS

Exam. Init.	Ref. Desig.	Document No.	Publication Date	Country or Patent Office	Class	Sub Class	Trans YES	lation NO
	AC-1							

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Exam. Init.	Ref. Desig.	Description		
	AD-1			

Examiner:

Date Considered:

1/6/9

EXAMINER! Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

												1
H PTC	-144	9	1-4	ATTY DOCK	ET NO.:	PP09	26.1	05				
ORKAT	NOI	DISCLOSURE ST	ATEHENT _	APPLICANT: Huston et al.								
			1 (Serial No	.: 09/55	8,74	1					
				FILING D	ATE: 4/2	6/00)		GROUP:	una	ssign	ed
			'-	PATENT			•					
<u>и.</u> [DOCURENT	0.5				CLASS		SUB CLAS		FILING DATE IF APPROPRIAT	
IT.		NUMBER	DATE	NAHE			LIM	.55		-		
	AG_	5,258,498	11/02/93	Huston	et al.		530		350			
	HA	5,260,203	11/09/93	Ladner	et al.		435	<u> </u>	172.	3		
	AI	5,571,894	11/05/96	Wels e	t al.						· 	
	AJ	5,587,458	12/24/96	King e	t al		1		1		<u> </u>	
							1		\ \			
	<u> </u>	 										_
	<u> </u>	1		_1			<u> </u>					
		DOCUMENT	FOREI	GN PATENT	DOCUHER	rrs SU	В		LING		TRACT	ENGLISH
XAM. NIT.	1	NUMBER	DATE	CODE	CLASS	CI.	CLASS I	I DA	TE	ONLY		LANG Y/I
		1				<u> </u>		<u> </u>		ļ		
	<u> </u>			l	1 1	<u> </u>		<u> </u>		<u> </u>		<u> </u>
	1			· ·						\ \ !		
	-	-			 							
			<u> </u>	1	-	1		1		1		
	<u> </u>		İ	<u> </u>				_1		1		
			OTHER AR	T, JOURN	AL ARTIC	LES,	ETC	•				
EXA				FILIN	G DATE:				GR	OUP:		
		CCCC Houst	on, Abstrac	ct from N	IH Grant	, Se	rial	No.	UO1	CA518	<u>80-05</u>	•
	•											
 		CCCD Pluc	kthun (1992) "Mono-	and Biva	lent	: Ant	ibo	dy Fra	gment	s Pro	duced in
1		Escherichia	coli: Engi	neering,	Folding	and	Anti	gen	Bindi	ng,"	Immun	ological
<u> </u>		Reviews, 13	<u>0: 151-188.</u>									···
	• •											
<u> </u>							- :					<u> </u>
 PYA	HINE	R	•		1	DATE	CONS	SIDE	RED .			

FORH PTO	-1449		ATTY DOCKET	NO.: PP0926.1	.05
INFORMAT:	ION DISC	LOSURE STATEMENT	l I APPLICANT: H	uston et al.	
•			Serial No.: (-
EXAM. INIT.	·		FILING DATE:	· · · · · · · · · · · · · · · · · · ·	GROUP: unassigned
	CCQ	Wels et al. (1992) Cancer Resea	rch, Vol. 52,	pp. 6310-6317, "Selective
		Toxin Specific fo			ant Single-Chain Antibody
	CCR	234-241, "Rapid I	nfarct Imaging	vith a Techni	Medicine, Vol. 34, pp. tium-99m-Labeled Anti-
		Acute Hyocoardial		I LA: FASTNSCIO	n in a Canine Hodel of
	ccs	Antibody Immunoco	njugates for (Cancer, "Demons	Conference on Monoclonal Stratioon of in vivo
	CCT	specificity of 12			
			remical Societ	ies Heeting, Du	edings of the 21st Federal ublin, pp. 47-60, "Single-usion proteins"
	ccu	McCartney et al.	(1993) Biotec	hnology, Advanc	ces in Gene Technology
		Technology Winter	Symposium, " (sFv'): Form	Refolding of S ation of Disul	of the 1993 Kiami Bio/ ingle-Chain Fv with c- fide-Bonded Homodimers of
	ccv	Huston et al. (19	993) Intern. R tions of Singl	ev. Immunol., e-Chain Antibo	Vol. 10, pp. 195-217, dies"
	CCA	Conference, "Dem	onstration of	in vivo tumor	International Hammersmith specificity of monovalent
		Fv molecule"	ms or 1251-741	re srv, an ant	i-c-erbB-2 single-chain
	CCX	"Refolding and C C-terminal cyste	haracterization ine (sFv): phy vivo of monova	on of single-chysicochemical balent sFv and b	Oth Hammersmith Heeting hain Fv analogues having behavior in vitro and tumor divalent (sFv) species digoxin"
	CCY	Holliger et al.	(1993) Proc. : :: Small bival	Natl. Acad. Sc: ent and bispec	i. USA, Vol. 90, pp. 6444- ific antibody fragments"
	· CCZ	Adams et al. (19	993) Cancer Re	search, Vol. 5 . Honovalent an	3, pp. 4026-4034, "Highly d Divalent Forms of 741F8
	CCCA	Jacobs (1991) B	ingle-Chain Fv	7 11	
	CCCB	Reichmann et al			7.
EXAHIN	ER ER		•	DATE CONSIDER	RED

FORM PTO	-1449		ATTY DOCKET NO.: PP0926.105
INFORMAT	TON DISC	LOSURE STATEMENT	APPLICANT: Huston et al.
			Serial No.: 09/558,741
EXAM. INIT.			
TUII.	T		FILING DATE: 4/26/00 GROUP: unassigned
	CCE	Whitlow et al. (19	991), Kethods: A Companion to Methods in
		Proteins and Thei	2, No. 2, pp. 97-105, "Single-Chain F⊽ r Fusion Proteins"
	CCF	Nedelman of al (1001) Abatmat Fam for Cairetific D. W. 20070
	1001	The Society of Nu	1991) Abstract Form for Scientific Papers, No. 32070 clear Medicine 38th Annual Meeting, "Rapid Infarct
	1	Imaging with a Ne Hyocardial Infarc	v Tc-99m Antimyosin sFv Fragment: Evaluation in Acute
	CCG	Waldmann (1991) S	cience, Vol. 252, pp. 1657-1662, "Monoclonal gnosis and Therapy"
	j		·
	ССН	Clackson et al. (fragments using n	1991) Nature, Vol. 352, pp. 624-628, "Making antibody bhage display libraries"
	i cor		
	CCI	"Identity of BCA2) Molecular Immunology, Vol. 28, No. 8, pp. 915-917, 200 and c-erbB-2 Indicated by Reactivity of Monoclonal
		Antibodies with R	Recombinant c-erbB-2"
	CCJ	 Milenic et al. (1	1991) Cancer Research, Vol. 51, pp. 6363-6371,
		l"Construction, Bi	inding Properties. Metabolism, and Tumonr Targeting of
		CC49"	Derived from the Pancarcinoma Monoclonal Antibody
	CCV		
	CCK	pp. 1-7, "Diminut	2) J. Steroid Biochem. Holec. Biol., Vol. 43, No. 1-3, tion of Antibodies Directed Against Tumor Cell Surface
,		Epitopes: A Sing	le Chain Fy Fusion Molecule Specifically Recognizes the
		Extracellular Dor	main of the c-erbB-2 Receptor"
	CCL	Pack et al. (199)	2) Biochemistry, Vol. 31, No. 6, pp. 1579-1584,
		Flexibility Link	Use of Amphipathic Helics To Produce Functional, ed Dimeric Fv Fragments with High Avidity in Escheri-
1	1	chia coli"	od Damona 1. 1244menes with high Avidity in Eschell-
	ссн	Yokota et al. (1	992) Cancer Research, Vol. 52, pp. 3402-3408, "Rapid
		Tumor Penetratio	n of a Single-Chain Fv and Comparision with Other
		Immunoglobulin F	orms"
ļ	CCN	Cumber et al. (1	992) The Journal of Immunology, Vol. 149, No. 1,
		binant House Ant	mparative Stabilities in Vitro and in Vivo of a Recom- libody FvCys Fragment and a bisFvCys Conjugate"
	CCO	l.	
		Dacterial Expres	2) Biotechnology, Vol. 10, pp.1128-1132, "Construction, sion and Characterization of a Bifunctional Single-
	1	Chain Antibody-F	Phosphatase Fusion Protein Targeted to the Human ERBB-2
ļ			
ļ	CCP	Schott et al. (1	1992) Cancer Research, Vol. 52, pp. 6413-6417,
<u> </u>		Chelated Anticar	etabolic Patterns of Iodinated versus Radiometal ccinoma Single-Chain Fv Holecules"
EXAKIN	ER		DATE CONSIDERED
		;	1 PULL COUSTDEVEN

ORH PTO	-1449		ATTY DOCKET NO.: PP0926.105	
INFORMAT	CION DIS	CLOSURE STATEMENT	APPLICANT: Huston et al.	
		i i		
EXAH.		<u> </u>	Serial No.: 09/558,741	·
INIT.		1	FILING DATE: 4/26/00	CDOMP
]		GROUP: unassigned
	CR	Ring et al. (1989)	Cancer Research Vol. 49, No.	11, pp. 3070-3080.
	1	i c - r c c r c c c c c c c c c c c c	ENVSICAL FEODPERIDE AT RETION	- V 100 000 01
	į ·	process selectives	y Associated with Human Breas	t Cancer"
	CS	Dillman (1989), A	nnals of Internal Hedicine, V	ol. 111. nn 592-603
	ì	"Honoclonal Antibo	dies for Treating Cancer"	- · · · · · · · · · · · · · · · · · · ·
	CT	Glockshuher et al	(1990) Ricchemiature V.J. co	
	·	"A Comparison of S	(1990) Biochemistry, Vol. 29 trategies to Stabilize Immuno	, pp. 1362-1367,
				<u>.</u>
	Cu	Queen et al. (1989) Proc. Natl. Acad. Sci., Vol	. 86, pp. 10029-10033,
	i	A numanized antib	ody that binds to the interle	ukin 2 receptor"
	CV	Hird et al. (1990)	Genes and Cancer, pp. 183-18	Q "Tmmunothoron-
		with Monoclonal An	tibodies"	5, indicatorierapy
	CW	Batter of all (1000) m	
	10.	No. 25. pp. 15198-) The Journal of Biological C	hemistry, Vol. 265,
	j	Pseudomonas Fusion	15202, "Anti-Tac(Fv)-PE40, a Protein Directed at Interleu	Single Chain Antibody
	1	Bearing Cells"	Troces at interieu	kin 2 keceptor
	CX	IV-C		
	T CX	No 12 pp 1006 1	90) Journal of the National C	ancer Institute, Vol. 82
	j	Negative Breast Ca	ULJ, "NOW LO USP Prognostic F	actors in Axillary Node-
	CY	Shealy et al. (199	0) The Journal of Nuclear Med	licine, Vol. 31, No. 5.
	ì	1 DOCK ITO	CERTIONS OF THE 4/th Annual Wa	
	İ	Antibody Fv Fragme	and Biodistribution of Tc-99m	Labeled Single Chain
	107			
<u> </u>	CZ	Colcher et al. (19	90) J. Natl. Cancer Inst., Vo	ol. 82, No. 14, pp. 1192
		Binding Protein"	nor Targeting of a Recombinant	Single-Chain Antigen-
			•	
	CCA	Batra et al. (1990)) Biochemical and Biophysical	Research Communication
	1	1.000 2/11 110. 1.)U. 1-0. "IL-P2-20F1-T26/F61 DI	240: A Bifunctional Toxi
	i	STOROXIC TOL CELL	s with EGF or IL2 Receptors"	
	ССВ	Tai et al. (1990)	Biochemistry, Vol. 29, pp. 80	124_8030 UA Bif
			ILALULUY FC-DINGING PRAGMANE /	1+ H 0+ C++=L-31
	· 1	Protein A Amino Te	erminal to Antidigoxin Single	-Chain Fv"
	lccc	1		
		toxicity, Second	00) Bispecific Antibodies and International Conference, pp.	Targeted Cellular Cyto-
		Single-Chain Fv Fu	ision Proteins"	201-200, "bifunctional
	l CCD			
	- 1-000	1203 pp 44 00 #	90) Academic Press, Inc., Het	hods in Enzymology, Vol.
	<u>i</u>	Fusion Proteins	Protein Engineering of Single	-Chain Fv Analogs and
EYANTU-	D			
EXAMINE	<u>r</u>		DATE CONSIDERED	

FORM PTO	-1449		ATTY DOCKET NO.: PP0926.105
		SCLOSURE STATEMENT	
11(1 ()()	ZON DIO	ODOBORU SIAIEMENI	APPLICANT: Huston et al.
EXAH.			<u>Serial No.: 09/558,741</u>
INIT.			FILING DATE: 4/26/00 GROUP: unassigned
	CE	Bjorn et al. (198	5) Cancer Research, Vol. 45, pp. 1214-1221,
	1	"Evaluation of Hor Cancer Immunotoxin	nocolonal Antibodies for the Development of Breast
	CF	Fisher et al (19)	86) Journal of Clinical Occale with the
	-	(JAJ-J41, "len-lea:	86) Journal of Clinical Oncology. Vol. 4, No. 6, pp. Results From the National Surgical Adjuvant Breast
	 	land power brolect	(NSABP) Clinical Trial Evaluating the Nee of Juphenyal
		1	(L-PAH) in the Hanagement of Primary Breast Cancer"
	- CG	Satov et al. (198	6) J. Hol. Biol., Vol. 190, pp. 593-604, "Phosphocho-
		at 2.7 A"	noglubolin Fab McPC603 An X-ray Diffraction Study
	l Cu		
	CH	Structure of An A) Science, Vol. 233, pp. 747-753, "Three-Dimensional ntigen-Antibody Complex at 2.8 A Resolution"
		į	
	CI	Sheriff et al. (1	987) Proc. Natl. Acad. Sci. USA, Vol. 84, pp. 8075-
		ļ	nsional structure of an antibody-antigen complex"
	CJ		87) Nature, Vol. 326, pp. 358-363, "Three-dimensional mplex of antibody with influenza virus neuraminidase"
!	l ICK	1	
	1	1 Majavant Iamoxil	987) The Lancet, Vol. II, No. 8552, pp. 171-175, en in the Management of Operable Breast Cancer:
 !		The Scottish Tria	1"
	CL	Aisner et al., (1	987) Journal of Clinical Oncology, Vol. 5, No. 10, pp.
		Tabello Tiento	CHELTADY VELSUS EDEMOIMMUNOTHERANY (CAF & CAFUD & CMC
! [Each ± HER) for H	Metastatic Carcinoma of the Breast : A CALGB Study"
	Сн	Huston et al. (19	988) Proc. Natl. Acad. Sci., Vo. 85, pp. 5879-5883,
<u> </u>		I Trocern engineer	INV OF ANTIBODY hinding citer. Percepture of checific
j		Eschericha coli"	ILI-digoxin single-chain by analogue produced in
1	l CV		
	CN	Sefton (1988) Tre	ends in Genetics, Vol. 4, No. 9, pp. 247-248, "neus
•			
	CO	Bird, et al. (198	38) Science, Vol. 242, pp. 423-426, "Single-Chain
1		Antigen-Binding I	rroteins"
<u> </u>	CP	Vogel et al. (198	88) Biochemistry, Vol. 28, pp. 2961-2966, "Binding
	l 1	Domains and Epito	opes in Platelet-Derived Growth Factor"
<u> </u>	Ico	Orlandi et al. (1989) Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 3833-
i	1	13037, CIONING IN	mmunoglobulin Variable domains for expression by the
1	-	polymerase chain	reaction"
EXAMINE	R		DATE CONSIDERED

ORH P	TO-144	49		ATTY DOCKET NO.: PP0926.105							
nforn	MOITA	DISCLOSURE ST	TATEHENT.	APPLICANT: Huston et al. Serial No.: 09/558,741							
				FILING I	DATE: 4/	26/00	 GROUP:	: u'nassign	ed		
			FOREI	CN PATENT	DOCUHEN	rs					
.TIM	l l	DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG Y/N		
	BF	W093/11161	06/10/93	PCT		1					
	 BG	W093/11162	06/10/93	PCT							
	BH	W093/15210	 08/05/93	PCT	1		T .				
	1					i					
· · · · · · · · · · · · · · · · · ·											
					İ				İ		
			İ								
			i ·		1				- [
				<u> </u>							
	<u> </u>		 								
<u> </u>	İ					1					
						1	<u> </u>		-		
					-						
	1			<u> </u>	-						
									·		
				1	-				-\ <u> </u>		
								1.	-		
	·										
							1				
			_				1	1			
				1							
				<u> </u>	1		1				
EXAH	THER				DA	TE CONSI	DERED				

ORH P	TO-14	449			ATTY DO	CKET NO.	: PPC	0926.10	5 			·		
CNFORH	ATIO	N DISC	LOSTRE S	TATEMENT	APPLICANT: Huston et al.									
					Serial	No.: 09	/558,7	741				-		
					FILING	DATE: 4	/26/00	0	GROUP	una	assig	ned		
		1 200		υ.	S. PATENT	DOCUREN	TS							
NIT.	ļ	NOK	UHENT BER	DATE	NAI	NAME			SUB CLAS			NG DATE PPROPRIATE		
	AA	4,47	2,509	09/18/84	Gansov	et al.		436	 548	·		·		
	AB	4,47	9,930	10/30/84	Hnatowi	ich		424	1.1			•		
· -	AC	4,75	3,894	06/28/88	Franke	l et al.		436	 548_					
	AD	4,94	6,778	08/07/90	Ladner	et al.		435	69.6					
	AE	5,09	1,513	02/25/92	Huston	et al.		530	387					
	AF 5,132,405		07/21/92	Huston	et al.		530	387.3						
	<u> </u>	<u>i</u>						1	· 		<u> </u>			
HAX.		1 000		FOREI	GN PATEN									
INIT.	-	•	UHENT BER	DATE	COUNTRY CODE	CLASS	SUB CLA	•	LING TE	ABST.	•	ENGLISH LANG Y/N		
	BA	V085	/03523	08/15/85	PCT	<u> </u>								
	ВВ	W088	/09344	01/12/88	PCT	1		- <u>l</u>						
	ВС	0502	812 A1	09/09/92	EPO	 	<u> </u>	1						
	BD	W092	/15682	09/17/92	PCT	<u> </u>					,			
	BE	W093	3/06217	04/01/93	PCT									
				OTHER AR	I, JOURNA	L ARTICL	ES, E	ETC.	· · · · · · · · · · · · · · · · · · ·			•		
EXAX TINI	•		<u></u>		FILING	DATE:			GROU	P:	•			
		CA_	Saul et	al. (1978) The Jou	rnal of	Biolo	ogical	Chemict	F11 1	/o1	253, No. 2		
	į Į		177. 303	-597, "Pre t from Hum	TIMINALA	Keilneme	ent ar	id Stru	rtural	Analt	teie	of the Fal		
	1	CB ==	l				-							
	İ		LTHEALCE	al. (1980 Imaging o enetriamin	T VUETOOC	nes to (מתוחה.	e Cardi	ac Hyos	195-2 in w	297, ith I	"Hyocardi .ndium-111		
	i	cc	1				•							
	i		Kunkel (1985) Proc. Natl. Acad. Sci. Vol. 82, pp. 488-492, "Rapid and efficient site-specific mutagenesis without phenotypic selection"											
			efficie	<u>nt site-sp</u>	ecilic mu	LOKCHES.	Chen et al. (1985) DNA, Vol. 4, No. 2, pp. 165-170,							
			ETTICIE	nt site-sp						oic s	етест	cion"		
		CD	Chen et	nt site-sp) DNA. V	ol. 4. Na	n. 2	nn 16	5-170					